IT-101 clinical trials
Also written CRLX101 and NLG207.
- studies test it
- 15
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How each study uses IT-101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2012 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 7
NewLink Genetics Corporation (6) · Ellipses Pharma (2) · National Cancer Institute (NCI) (2) · Abramson Cancer Center at Penn Medicine (1) · Massachusetts General Hospital (1) · City of Hope Medical Center (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Chicago (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses IT-101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung CancerTerminatedPhase 1/2National Cancer Institute (NCI)NCT02769962Written as EP0057
- A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerTerminatedPhase 1/2NewLink Genetics CorporationNCT02389985Written as CRLX101
- EP0057 in Combination With Olaparib in Advanced Ovarian CancerCompletedPhase 2Ellipses PharmaNCT04669002Written as EP0057
- EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung CancerWithdrawnPhase 2Ellipses PharmaNCT05411679Written as EP0057
- Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide TreatmentTerminatedPhase 2National Cancer Institute (NCI)NCT03531827Written as CRLX101
- Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal CancerTerminatedPhase 1/2UNC Lineberger Comprehensive Cancer CenterNCT02010567Written as CRLX101
- Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung CancerTerminatedPhase 2University of ChicagoNCT01803269Written as cyclodextrin-based polymer-camptothecin CRLX101
- Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.WithdrawnPhase 2NewLink Genetics CorporationNCT00753740Written as IT-101 (12mg/m2/dose)
- A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung CancerCompletedPhase 2NewLink Genetics CorporationNCT01380769Written as CRLX101
- Study of CRLX101 (NLG207) in the Treatment of Advanced Solid TumorsCompletedPhase 1/2NewLink Genetics CorporationNCT00333502Written as Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
- CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)CompletedPhase 2NewLink Genetics CorporationNCT02187302Written as CRLX101
- Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid TumorsTerminatedPhase 1NewLink Genetics CorporationNCT02648711Written as CRLX101
- CRLX101 Plus Bevacizumab in Advanced RCCCompletedPhase 1Abramson Cancer Center at Penn MedicineNCT01625936Written as CRLX101 (Cerulean)
- CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal CancerCompletedPhase 2Massachusetts General HospitalNCT01652079Written as CRLX101
- Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by SurgeryCompletedPhase 2City of Hope Medical CenterNCT01612546Written as cyclodextrin-based polymer-camptothecin CRLX101